MAGE-TAB Version 1.1 Comment[MetaboBank accession] MTBKS279 Study Title Sphingolipid and Glycerophospholipid Profiling in Post-Acute Sequelae of SARS-CoV-2 Infection Study Description Several sphingolipid and glycerophospholipid profiles were modulated in the COVID-19 PASC compared to healthy control. Experimental Design observational design Experimental Factor Name disease_time_point Experimental Factor Type disease_time_point Person Last Name Yamamoto Kurano Person First Name Shinya Makoto Person Mid Initials Person Affiliation Graduate School of Medicine, The University of Tokyo Graduate School of Medicine, The University of Tokyo Person Roles submitter submitter PubMed ID Publication DOI Protocol Name Sample collection Extraction Chromatography 1 Chromatography 2 Mass spectrometry 1 Mass spectrometry 2 Data processing 1 Data processing 2 Metabolite identification 1 Metabolite identification 2 Protocol Type Sample collection Extraction Chromatography Chromatography Mass spectrometry Mass spectrometry Data processing Data processing Metabolite identification Metabolite identification Protocol Description We collected residual serum samples from participants diagnosed with COVID-19 who had not received prior SARS-CoV-2 vaccination between April 2020 and June 2021. The diagnosis was based on reverse transcription polymerase chain reaction (RT-PCR) assay results. We aimed to collect one sample from each participant at as many of the following eight timepoints as possible: pre-onset, Days 1-3, 4-6, 7-9, 10-12, 13-15, 16-18, 19-24, and beyond Day 25. Considering the diverse timing of RT-PCR testing among patients, we used the day following symptom onset as the initial measurement in our lipid modulation investigation. For sphingolipids, 10 μL of each serum sample was combined with 10 μL of internal standards (SPLASH LipidoMix, Cer1P-d7, HexCer, C17S1P, C17dhS1P, C17:1 sphingosine [Sph], C17:1 dihydrosphingosine [dhSph], and d18:1/17:0 ceramide; Avanti Polar Lipids) to achieve a final concentration of 1 ng/mL. Sphingolipids were extracted by adding 100 μL of methanol containing 0.1% formic acid (Wako Pure Chemical Industries) and 80 μL of acetonitrile (Wako Pure Chemical Industries). For glycerophospholipids, two independent LC-MS/MS methods were used using an LC8060 system comprising a quantum ultra-triple quadrupole mass spectrometer (Shimadzu Corporation, Kyoto, Japan), as previously described and validated 19,20. Multiple glycerophospholipids were monitored, including LPC, LPS, LPE, LPG, LPI, PC, PE, PI, PG, and PS. We outsourced the analysis to Shimadzu Corporation. For sphingolipids, LC-MS/MS, 5.0 μL of each extract was injected and separated on a normal-phase column (U-Inert Sustain Swift Amide, 3 μm, 2.1 × 100 mm; UP). Gradient elution was performed at 0.6 mL/min using solvent A (10 mM ammonium acetate in 95% acetonitrile/5% water) and solvent B (10 mM ammonium acetate in 50% acetonitrile). The gradient program was as follows: 99% A/1% B for 1 min, 90% A/10% B for 1 min, 60% A/40% B for 3 min, and 20% A/80% B for 2 min, for a total run time of 11 min. Column and sample temperatures were maintained at 50°C and 10°C, respectively. We outsourced the analysis to Department of Clinical Laboratory, The University of Tokyo Hospital. As for glycerophospholipids, the analysis was outsourced to Shimadzu Corporation. Raw data cannot be obtained because the data retention period for contract analysis with Shimadzu Corporation has expired. Mass spectrometric detection was performed in positive electrospray ionization mode with cone gas at 50 L/h, desolvation gas at 1000 L/h, a source temperature of 150°C, and a desolvation temperature of 600°C. Sphingolipids were quantified using multiple reaction monitoring in positive-ion mode, and data were processed with MassLynx and TargetLynx XS (Waters Corporation). Raw data cannot be obtained because the data retention period for contract analysis with Department of Clinical Laboratory, The University of Tokyo Hospital has expired. "Data processing and analysis were conducted using JMP Pro (version 17, SAS Institute, Tokyo, Japan), Statistical Package for the Social Sciences (Chicago, IL, USA), Metaboanalysis 6.0 (https://www.metaboanalyst.ca/), and GraphPad Prism 9.0 software (GraphPad Software, San Diego, CA, USA). This approach enabled monitoring of multiple sphingolipid species, including Cer1P species, Lac Cer species, dhCer species, Deoxy dhCer species, DeocyCer species, S1P species, dhS1P species, Sph species, dhSph species, Cer species, Hex Cer species, and SM species. Assay performance was reliable, with coefficients of variation below 20%." "Data processing and analysis were conducted using JMP Pro (version 17, SAS Institute, Tokyo, Japan), Statistical Package for the Social Sciences (Chicago, IL, USA), Metaboanalysis 6.0 (https://www.metaboanalyst.ca/), and GraphPad Prism 9.0 software (GraphPad Software, San Diego, CA, USA). This approach enabled monitoring of multiple sphingolipid species, including Cer1P species, Lac Cer species, dhCer species, Deoxy dhCer species, DeocyCer species, S1P species, dhS1P species, Sph species, dhSph species, Cer species, Hex Cer species, and SM species. Assay performance was reliable, with coefficients of variation below 20%. For glycerophospholipids, two independent LC-MS/MS methods were used using an LC8060 system comprising a quantum ultra-triple quadrupole mass spectrometer (Shimadzu Corporation, Kyoto, Japan), as previously described and validated. Multiple glycerophospholipids were monitored, including LPC, LPS, LPE, LPG, LPI, PC, PE, PI, PG, and PS." Data not submitted. Data not submitted. Protocol Parameters Post extraction;Derivatization Chromatography instrument;Autosampler model;Column model;Column type;Temperature;Guard column Chromatography instrument;Autosampler model;Column model;Column type;Temperature;Guard column Scan polarity;Scan m/z range;Instrument;Ion source;Mass analyzer Scan polarity;Scan m/z range;Instrument;Ion source;Mass analyzer Protocol Hardware Protocol Software Public Release Date 2026-05-22 Term Source Name Term Source File Term Source Version SDRF File MTBKS279.sdrf.txt Comment[Study type] lipid profiling Comment[Experiment type] liquid chromatography-mass spectrometry Comment[Submission type] LC-MS Comment[BioProject] PRJDB40156 Comment[Related study] Comment[Contributor] Comment[Submission Date] 2026-02-25 Comment[Last Update Date] 2026-05-22